Perth, May 15, 2017 AEST (ABN Newswire) – MMJ PhytoTech Limited (ASX:MMJ) (“MMJ” or “the Company”) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited (“PTL”), has received Helsinki (IRB of Sheba Clinical Site) and Ministry of Health (“MOH”) approvals for the conducting of its Phase 2 clinical study into the safety and efficacy of its PTL201 capsules in treating spasticity related symptoms of multiple sclerosis (“MS”) patients.
– 100%-owned subsidiary, PhytoTech Therapeutics, receives Clinical Site and Ministry of Health approvals to conduct Phase 2 clinical trial of PTL201
– Phase 2 clinical trial is aimed at measuring safety and efficacy of the PTL201 capsules in treating spasticity related symptoms in multiple sclerosis (MS) patients
– Phase 2 clinical trial is double-blind, randomised, placebo-controlled, parallel-group study in 70 MS patients
– Success of Phase